Browse > Article
http://dx.doi.org/10.5483/BMBRep.2019.52.2.011

E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway  

Woo, Seon Min (Department of Immunology, School of Medicine, Keimyung University)
Kwon, Taeg Kyu (Department of Immunology, School of Medicine, Keimyung University)
Publication Information
BMB Reports / v.52, no.2, 2019 , pp. 119-126 More about this Journal
Abstract
The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) initiates the extrinsic apoptotic pathway through formation of the death-inducing signaling complex (DISC), followed by activation of effector caspases. TRAIL receptors are composed of death receptors (DR4 and DR5), decoy receptors (DcR1 and DcR2), and osteoprotegerin. Among them, only DRs activate apoptotic signaling by TRAIL. Since the levels of DR expressions are higher in cancer cells than in normal cells, TRAIL selectively activates apoptotic signaling pathway in cancer cells. However, multiple mechanisms, including down-regulation of DR expression and pro-apoptotic proteins, and up-regulation of anti-apoptotic proteins, make cancer cells TRAIL-resistant. Therefore, many researchers have investigated strategies to overcome TRAIL resistance. In this review, we focus on protein regulation in relation to extrinsic apoptotic signaling pathways via ubiquitination. The ubiquitin proteasome system (UPS) is an important process in control of protein degradation and stabilization, and regulates proliferation and apoptosis in cancer cells. The level of ubiquitination of proteins is determined by the balance of E3 ubiquitin ligases and deubiquitinases (DUBs), which determine protein stability. Regulation of the UPS may be an attractive target for enhancement of TRAIL-induced apoptosis. Our review provides insight to increasing sensitivity to TRAIL-mediated apoptosis through control of post-translational protein expression.
Keywords
Deubiquitinase; DISC; E3 ligase; Extrinsic pathway; TRAIL;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ikeda F and Dikic I (2008) Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep 9, 536-542   DOI
2 Kirisako T, Kamei K, Murata S et al (2006) A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 25, 4877-4887   DOI
3 Roth W and Reed JC (2004) FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67, 189-206   DOI
4 Kulathu Y and Komander D (2012) Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 13, 508-523   DOI
5 Olzmann JA and Chin LS (2008) Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 4, 85-87   DOI
6 Shen M, Schmitt S, Buac D and Dou QP (2013) Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 17, 1091-1108   DOI
7 Ding F, Xiao H, Wang M, Xie X and Hu F (2014) The role of the ubiquitin-proteasome pathway in cancer development and treatment. Front Biosci (Landmark Ed) 19, 886-895   DOI
8 Orlowski RZ (1999) The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6, 303-313   DOI
9 Reyes-Turcu FE, Ventii KH and Wilkinson KD (2009) Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78, 363-397   DOI
10 Leznicki P and Kulathu Y (2017) Mechanisms of regulation and diversification of deubiquitylating enzyme function. J Cell Sci 130, 1997-2006   DOI
11 Nijman SM, Luna-Vargas MP, Velds A et al (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773-786   DOI
12 Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ and Urbe S (2013) Deubiquitylases from genes to organism. Physiol Rev 93, 1289-1315   DOI
13 Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R and Olumi AF (2004) Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 64, 7086-7091   DOI
14 Shirley S and Micheau O (2013) Targeting c-FLIP in cancer. Cancer Lett 332, 141-150   DOI
15 Griffith TS, Chin WA, Jackson GC, Lynch DH and Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161, 2833-2840
16 Xiao CW, Yan X, Li Y, Reddy SA and Tsang BK (2003) Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 144, 623-630   DOI
17 Valnet-Rabier MB, Challier B, Thiebault S et al (2005) c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 128, 767-773   DOI
18 Valente G, Manfroi F, Peracchio C et al (2006) cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy. Br J Haematol 132, 560-570   DOI
19 Lafont E, Kantari-Mimoun C, Draber P et al (2017) The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J 36, 1147-1166   DOI
20 Komander D, Clague MJ and Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563   DOI
21 Abdul Rehman SA, Kristariyanto YA, Choi SY et al (2016) MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. Mol Cell 63, 146-155   DOI
22 Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosisinducing ligand in vivo. Nat Med 5, 157-163   DOI
23 Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH and Durrant LG (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13, 5070-5075   DOI
24 Bielskiene K, Bagdoniene L, Mozuraitiene J, Kazbariene B and Janulionis E (2015) E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas) 51, 1-9   DOI
25 D'Arcy P, Wang X and Linder S (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther 147, 32-54   DOI
26 Nicholson B, Marblestone JG, Butt TR and Mattern MR (2007) Deubiquitinating enzymes as novel anticancer targets. Future Oncol 3, 191-199   DOI
27 Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104, 155-162   DOI
28 Wang S and El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22, 8628-8633   DOI
29 Pan G, O'Rourke K, Chinnaiyan AM et al (1997) The receptor for the cytotoxic ligand TRAIL. Science 276, 111-113   DOI
30 Sheridan JP, Marsters SA, Pitti RM et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821   DOI
31 Srivastava RK (2001) TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3, 535-546   DOI
32 Zhao L, Yue P, Khuri FR and Sun SY (2013) mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis. Cancer Res 73, 1946-1957   DOI
33 Chang L, Kamata H, Solinas G et al (2006) The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124, 601-613   DOI
34 Yang F, Tay KH, Dong L et al (2010) Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death Differ 17, 1354-1367   DOI
35 Seo BR, Min KJ, Woo SM et al (2017) Inhibition of cathepsin s induces mitochondrial ros that sensitizes trail-mediated apoptosis through p53-Mediated Downregulation of Bcl-2 and c-FLIP. Antioxid Redox Signal 27, 215-233   DOI
36 Hsu TS, Mo ST, Hsu PN and Lai MZ (2018) c-FLIP is a target of the E3 ligase deltex1 in gastric cancer. Cell Death Dis 9, 135   DOI
37 Haimerl F, Erhardt A, Sass G and Tiegs G (2009) Down-regulation of the de-ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 284, 495-504   DOI
38 Panner A, Crane CA, Weng C et al (2010) Ubiquitinspecific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer Res 70, 5046-5053   DOI
39 Jeong M, Lee EW, Seong D et al (2017) USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability. Oncogene 36, 458-470   DOI
40 Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ and Ashkenazi A (2000) Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611-620   DOI
41 Kantari C and Walczak H (2011) Caspase-8 and bid: caught in the act between death receptors and mitochondria. Biochim Biophys Acta 1813, 558-563   DOI
42 Song JJ, Szczepanski MJ, Kim SY et al (2010) c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal 22, 553-563   DOI
43 Zhang L and Fang B (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12, 228-237   DOI
44 Jin Z, McDonald ER 3rd, Dicker DT and El-Deiry WS (2004) Deficient tumor necrosis factor-related apoptosisinducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem 279, 35829-35839   DOI
45 Zhang Y and Zhang B (2008) TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6, 1861-1871   DOI
46 Kim SY, Kim JH and Song JJ (2013) c-Cbl shRNAexpressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5. Cancer Gene Ther 20, 82-87   DOI
47 D'Arcy P, Brnjic S, Olofsson MH et al (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17, 1636-1640   DOI
48 van de Kooij B, Verbrugge I, de Vries E et al (2013) Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. J Biol Chem 288, 6617-6628   DOI
49 Park EJ, Min KJ, Choi KS et al (2016) Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells. Sci Rep 6, 22921   DOI
50 D'Arcy P and Linder S (2012) Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol 44, 1729-1738   DOI
51 Bosu DR and Kipreos ET (2008) Cullin-RING ubiquitin ligases: global regulation and activation cycles. Cell Div 3, 7   DOI
52 Oh YT, Deng L, Deng J and Sun SY (2017) The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5. Sci Rep 7, 8027   DOI
53 Oh YT, Qian G, Deng J and Sun SY (2018) Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activationinduced apoptosis through its deubiquitinase function. Oncogene 37, 3415-3425   DOI
54 Jin Z, Li Y, Pitti R et al (2009) Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137, 721-735   DOI
55 Li Y, Kong Y, Zhou Z et al (2013) The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis 4, e935   DOI
56 Petroski MD and Deshaies RJ (2005) Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 6, 9-20   DOI
57 Gonzalvez F, Lawrence D, Yang B et al (2012) TRAF2 Sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell 48, 888-899   DOI
58 Xu L, Zhang Y, Qu X et al (2017) DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells. Mol Oncol 11, 1733-1751   DOI
59 Zhou Z, Liu R and Chen C (2012) The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer. Int J Cancer 130, 1504-1510   DOI
60 Christian PA, Fiandalo MV and Schwarze SR (2011) Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer 10, 57   DOI
61 Ravid T and Hochstrasser M (2008) Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9, 679-690   DOI
62 Hershko A and Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67, 425-479   DOI
63 Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70, 503-533   DOI
64 Finley D, Ciechanover A and Varshavsky A (2004) Ubiquitin as a central cellular regulator. Cell 116, S29-32, 2 p following S32   DOI
65 Deshaies RJ and Joazeiro CA (2009) RING domain E3 ubiquitin ligases. Annu Rev Biochem 78, 399-434   DOI
66 Joazeiro CA and Weissman AM (2000) RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549-552   DOI
67 Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J and Hood L (1997) Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 7, 821-830   DOI
68 Bodmer JL, Holler N, Reynard S et al (2000) TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2, 241-243   DOI
69 Sprick MR, Weigand MA, Rieser E et al (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599-609   DOI
70 Lee EW, Kim JH, Ahn YH et al (2012) Ubiquitination and degradation of the FADD adaptor protein regulate death receptor-mediated apoptosis and necroptosis. Nat Commun 3, 978   DOI
71 Hsu H, Shu HB, Pan MG and Goeddel DV (1996) TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299-308   DOI
72 Sessler T, Healy S, Samali A and Szegezdi E (2013) Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling. Pharmacol Ther 140, 186-199   DOI
73 Christofferson DE, Li Y and Yuan J (2014) Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol 76, 129-150   DOI
74 Wertz IE, O'Rourke KM, Zhou H et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430, 694-699   DOI
75 Bellail AC, Olson JJ, Yang X, Chen ZJ and Hao C (2012) A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov 2, 140-155   DOI
76 Dong B, Lv G, Wang Q et al (2012) Targeting A20 enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 418, 433-438   DOI